Ítem
Solo Metadatos

Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes

Mostrar el registro sencillo de la publicación
dc.creatorUmpierrez G.E.spa
dc.creatorO'Neal D.spa
dc.creatorDiGenio A.spa
dc.creatorGoldenberg R.spa
dc.creatorHernandez-Triana E.spa
dc.creatorLin J.spa
dc.creatorPark C.-Y.spa
dc.creatorRenard E.spa
dc.creatorKovatchev B.spa
dc.date.accessioned2020-05-26T00:06:02Z
dc.date.available2020-05-26T00:06:02Z
dc.date.created2017spa
dc.description.abstractChronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic variability (GV) vs placebo as add-on to basal insulin. The main outcome GV measures were standard deviation (s.d.), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG) level, area under the curve for fasting glucose (AUC-F), and high (HBGI) and low blood glucose index (LBGI). The change in GV metrics over 24 weeks and relationships among baseline GV, patient characteristics and outcomes were assessed. Data were pooled from 1198 patients (665 LIXI, 533 placebo). Values for s.d., MAG level, MAGE, HBGI, and AUC-F significantly decreased with LIXI vs placebo, while LBGI values were unchanged. Higher baseline GV measures correlated with older age, longer type 2 diabetes duration, lower body mass index, higher baseline glycated/haemogobin, greater reduction in postprandial glucose (PPG) level, and higher rates of symptomatic hypoglycaemia. These data show that LIXI added to basal insulin significantly reduced GV and PPG excursions vs placebo, without increasing the risk of hypoglycaemia (LBGI). © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley and Sons Ltd.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1111/dom.12930
dc.identifier.issn14631326
dc.identifier.issn14628902
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23850
dc.language.isoengspa
dc.publisherBlackwell Publishing Ltdspa
dc.relation.citationEndPage1321
dc.relation.citationIssueNo. 9
dc.relation.citationStartPage1317
dc.relation.citationTitleDiabetes, Obesity and Metabolism
dc.relation.citationVolumeVol. 19
dc.relation.ispartofDiabetes, Obesity and Metabolism, ISSN:14631326, 14628902, Vol.19, No.9 (2017); pp. 1317-1321spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85018409885&doi=10.1111%2fdom.12930&partnerID=40&md5=5e8f83ce4df24056ec55d4a81a3bbe38spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordGlucosespa
dc.subject.keywordtype 2eng
dc.subject.keywordInsulinspa
dc.subject.keywordLixisenatidespa
dc.subject.keywordPlacebospa
dc.subject.keywordAntidiabetic agentspa
dc.subject.keywordGlp1r proteineng
dc.subject.keywordGlucagon like peptide 1 receptorspa
dc.subject.keywordGlycosylated hemoglobinspa
dc.subject.keywordHemoglobin a1c proteineng
dc.subject.keywordInsulinspa
dc.subject.keywordLixisenatidespa
dc.subject.keywordPeptidespa
dc.subject.keywordArticlespa
dc.subject.keywordBody massspa
dc.subject.keywordClinical effectivenessspa
dc.subject.keywordClinical evaluationspa
dc.subject.keywordDisease durationspa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordEndocrine functionspa
dc.subject.keywordFollow upspa
dc.subject.keywordGlucose blood levelspa
dc.subject.keywordGlycemic variabilityspa
dc.subject.keywordHemoglobin blood levelspa
dc.subject.keywordHumanspa
dc.subject.keywordHypoglycemiaspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMulticenter study (topic)spa
dc.subject.keywordNon insulin dependent diabetes mellitusspa
dc.subject.keywordPhase 3 clinical trial (topic)spa
dc.subject.keywordRandomized controlled trial (topic)spa
dc.subject.keywordAgonistsspa
dc.subject.keywordAnalysisspa
dc.subject.keywordBloodspa
dc.subject.keywordBlood glucose monitoringspa
dc.subject.keywordChemically inducedspa
dc.subject.keywordClinical trialspa
dc.subject.keywordCohort analysisspa
dc.subject.keywordCombination drug therapyspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug resistancespa
dc.subject.keywordHyperglycemiaspa
dc.subject.keywordHypoglycemiaspa
dc.subject.keywordIntention to treat analysisspa
dc.subject.keywordMetabolismspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordNon insulin dependent diabetes mellitusspa
dc.subject.keywordPathophysiologyspa
dc.subject.keywordPhase 3 clinical trialspa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordReproducibilityspa
dc.subject.keywordSeverity of illness indexspa
dc.subject.keywordBlood glucosespa
dc.subject.keywordBlood glucose self-monitoringspa
dc.subject.keywordCohort studiesspa
dc.subject.keywordDiabetes mellituseng
dc.subject.keywordDouble-blind methodspa
dc.subject.keywordDrug resistancespa
dc.subject.keywordDrug therapyeng
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordGlucagon-like peptide-1 receptorspa
dc.subject.keywordGlycated hemoglobin aspa
dc.subject.keywordHumansspa
dc.subject.keywordHyperglycemiaspa
dc.subject.keywordHypoglycemiaspa
dc.subject.keywordHypoglycemic agentsspa
dc.subject.keywordInsulinspa
dc.subject.keywordIntention to treat analysisspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPeptidesspa
dc.subject.keywordReproducibility of resultsspa
dc.subject.keywordSeverity of illness indexspa
dc.subject.keywordGlycaemic variabilityspa
dc.subject.keywordInsulinspa
dc.subject.keywordLixisenatidespa
dc.subject.keywordType 2 diabetesspa
dc.titleLixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetesspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos